ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Ann Thorac Surg 2009;87:1751-1756. doi:10.1016/j.athoracsur.2009.03.058
© 2009 The Society of Thoracic Surgeons
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Sven Lehmann
Thomas Walther
Sergey Leontyev
Jens Garbade
Michael A. Borger
Friedrich W. Mohr
Right arrow Permission Requests
Google Scholar
Right arrow Articles by Lehmann, S.
Right arrow Articles by Mohr, F. W.
PubMed
Right arrow Articles by Lehmann, S.
Right arrow Articles by Mohr, F. W.
Related Collections
Right arrow Valve disease

Original Articles: Adult Cardiac

The Toronto Root Bioprosthesis: Midterm Results in 186 Patients

Sven Lehmann, MD*, Thomas Walther, MD, PhD, Sergey Leontyev, MD, Jörg Kempfert, MD, Jens Garbade, MD, Michael A. Borger, MD, PhD, Friedrich W. Mohr, MD, PhD

Department of Cardiac Surgery, University of Leipzig, Heartcenter, Leipzig, Germany

Accepted for publication March 23, 2009.

* Address correspondence to Dr Lehmann, Universität Leipzig, Herzzentrum, Klinik für Herzchirurgie, Strümpellstr 39, Leipzig, 04289, Germany (Email: sven.lehmann{at}med.uni-leipzig.de).

Background: The Toronto Root bioprosthesis with BiLinx anticalcification treatment (St. Jude Medical, St. Paul, MN) was introduced into clinical practice in 2001, mainly for patients with aortic valve disease and additional pathology of the aorta. Patients included in the initial clinical study with core laboratory data evaluation were reviewed.

Methods: A total of 186 patients (62 ± 11 years, 38 female) received full root replacement at our institution with the Toronto Root bioprosthesis from June 2001 until November 2007. The predominant aortic valve lesion was stenosis in 34, incompetence in 80, and mixed lesions in 72 patients. Additional procedures included replacement of the ascending aorta in 139, replacement of the ascending aorta plus aortic arch in 38, coronary artery bypass graft surgery in 31, mitral valve repair in 26, atrial fibrillation ablation in 14, and atrial septal defect closure in 8 patients. Previous cardiac surgery had been performed in 10 patients. Mean follow-up was 50 ± 26 months (770 patient-years).

Results: The mean implanted valve size was 26.8 ± 1.8 mm (14 x 23 mm, 36 x 25 mm, 87 x 27 mm, and 48 x 29 mm). Aortic cross-clamp time was 99.8 ± 29 minutes, and cardiopulmonary bypass time was 140.9 ± 52 minutes. All patients showed a clinical improvement of at least one New York Heart Association class during follow-up. Most recent echocardiographic examination revealed a maximum transvalvular blood flow velocity of 2.1 ± 0.5 m/s and a mean pressure gradient of 9.6 ± 8.5 mm Hg. Left ventricular ejection fraction was 61% ± 11%. Early mortality was 5.9% ± 1.7%, and 5-year survival was 83.3% ± 3.0%. Patients who underwent isolated aortic root surgery had a 5-year survival of 90.3% ± 4.2%.

Conclusions: The Toronto Root bioprosthesis is safe and provides good clinical and hemodynamic function after full root replacement with or without additional aortic surgery. Owing to the specific anticalcification treatment, long-term durability may be promising.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2009 by The Society of Thoracic Surgeons.